Segall Bryant & Hamill LLC Acquires New Position in LeMaitre Vascular, Inc. (NASDAQ:LMAT)

Segall Bryant & Hamill LLC bought a new position in shares of LeMaitre Vascular, Inc. (NASDAQ:LMAT) during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund bought 59,106 shares of the medical instruments supplier’s stock, valued at approximately $5,446,000. Segall Bryant & Hamill LLC owned about 0.26% of LeMaitre Vascular at the end of the most recent quarter.

Other hedge funds have also bought and sold shares of the company. Advisors Asset Management Inc. increased its holdings in shares of LeMaitre Vascular by 180.2% in the third quarter. Advisors Asset Management Inc. now owns 1,852 shares of the medical instruments supplier’s stock valued at $172,000 after purchasing an additional 1,191 shares during the period. Intech Investment Management LLC purchased a new stake in LeMaitre Vascular in the third quarter valued at approximately $377,000. Charles Schwab Investment Management Inc. increased its holdings in LeMaitre Vascular by 6.3% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 191,511 shares of the medical instruments supplier’s stock worth $17,789,000 after buying an additional 11,395 shares during the period. The Manufacturers Life Insurance Company raised its position in LeMaitre Vascular by 7.7% during the 3rd quarter. The Manufacturers Life Insurance Company now owns 11,273 shares of the medical instruments supplier’s stock worth $1,047,000 after buying an additional 804 shares during the last quarter. Finally, Quantbot Technologies LP lifted its stake in LeMaitre Vascular by 3.3% during the 3rd quarter. Quantbot Technologies LP now owns 9,200 shares of the medical instruments supplier’s stock valued at $855,000 after acquiring an additional 292 shares during the period. Institutional investors and hedge funds own 84.64% of the company’s stock.

LeMaitre Vascular Trading Down 0.7 %

Shares of LMAT opened at $83.92 on Friday. The firm has a market cap of $1.89 billion, a P/E ratio of 45.86, a PEG ratio of 2.22 and a beta of 0.89. LeMaitre Vascular, Inc. has a 12 month low of $62.39 and a 12 month high of $109.58. The stock’s 50 day moving average is $93.39 and its two-hundred day moving average is $94.34.

LeMaitre Vascular (NASDAQ:LMAT) last released its quarterly earnings results on Thursday, February 27th. The medical instruments supplier reported $0.49 earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of $0.49. The firm had revenue of $55.81 million for the quarter, compared to analysts’ expectations of $55.99 million. LeMaitre Vascular had a net margin of 19.40% and a return on equity of 13.15%. Equities research analysts forecast that LeMaitre Vascular, Inc. will post 1.94 EPS for the current year.

LeMaitre Vascular Increases Dividend

The company also recently disclosed a quarterly dividend, which was paid on Thursday, March 27th. Investors of record on Thursday, March 13th were issued a $0.20 dividend. This represents a $0.80 annualized dividend and a yield of 0.95%. This is a boost from LeMaitre Vascular’s previous quarterly dividend of $0.16. The ex-dividend date of this dividend was Thursday, March 13th. LeMaitre Vascular’s payout ratio is presently 41.24%.

Analyst Upgrades and Downgrades

LMAT has been the topic of a number of research reports. StockNews.com lowered shares of LeMaitre Vascular from a “buy” rating to a “hold” rating in a research note on Friday, December 13th. Lake Street Capital increased their price target on LeMaitre Vascular from $105.00 to $110.00 and gave the stock a “buy” rating in a research report on Friday, February 28th. Barrington Research lowered LeMaitre Vascular from an “outperform” rating to a “market perform” rating in a research note on Friday, February 28th. Wells Fargo & Company initiated coverage on LeMaitre Vascular in a research note on Thursday, February 13th. They issued an “equal weight” rating and a $95.00 target price on the stock. Finally, Oppenheimer cut LeMaitre Vascular from an “outperform” rating to a “market perform” rating in a research report on Friday, February 28th. Five research analysts have rated the stock with a hold rating, four have assigned a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, LeMaitre Vascular has a consensus rating of “Moderate Buy” and an average target price of $95.25.

Insiders Place Their Bets

In related news, insider Trent G. Kamke sold 2,009 shares of the business’s stock in a transaction that occurred on Wednesday, March 12th. The stock was sold at an average price of $82.12, for a total transaction of $164,979.08. Following the completion of the sale, the insider now directly owns 5,564 shares in the company, valued at approximately $456,915.68. The trade was a 26.53 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. 10.79% of the stock is owned by company insiders.

LeMaitre Vascular Profile

LeMaitre Vascular, Inc develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature.